Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Head explodes: On March 23, 2020, the Biologics

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154829
(Total Views: 745)
Posted On: 06/01/2020 9:46:08 PM
Posted By: LOL83001
Head explodes:
On March 23, 2020, the Biologics Price Competition and Innovation Act of 2009 requires that an approved application for a “biological product” under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) shall be deemed to be a license for the biological product (i.e., an approved Biologics License Application (BLA)) under section 351 of the Public Health Service Act (PHS Act). FDA has assigned the same application number used for the approved new drug application (NDA) to the deemed BLA. However, an application holder whose NDA was deemed to be a BLA will need to ensure that the listing information for the biological product is updated in FDA’s electronic Drug Registration and Listing System (eDRLS) between March 23, 2020, and June 30, 2020, to reflect a change in the prefix of the application number (from “NDA” to “BLA”) (see 21 CFR 207.57(b)(1)(iv)). Until this occurs, the change in application type will not be reflected in this database, even though the application will be correctly described as a BLA in other databases.

FDA also notes that the deeming of an approved NDA to be a BLA and the corresponding update of the eDRLS listing information for the biological product to change the prefix for the application number will not result in the need for a new National Drug Code (NDC) number with a new product code. Accordingly, in the absence of other changes made by the application holder that would require a new NDC number, biological products approved under the FD&C Act will retain their current NDC number after the NDA is deemed to be a BLA.

For a list of approved NDAs for biological products that were deemed to be BLAs, please see FDA’s List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020.

For additional information please see FDA’s webpage on The “Deemed to be a License Provision of the BPCI Act”, including FDA’s guidance on The “Deemed to Be a License” Provision of the BPCI Act Questions and Answers.


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us